Connect with us

Technology

Flow Cytometer Market to Expand by USD 8.17 Billion (2024-2028), Rising R&D Investments Drive Growth, Report on AI’s Impact on Market Trends – Technavio

Published

on

NEW YORK, Nov. 26, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global flow cytometer market size is estimated to grow by USD 8.17 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of about 15.2% during the forecast period. Increasing expenditure on r and d is driving market growth, with a trend towards increasing level of process automation. However, high cost of instruments poses a challenge.Key market players include Abbott Laboratories, Agilent Technologies Inc., Amphasys AG, Apogee Flow Systems Ltd., Becton Dickinson and Co., Bio Rad Laboratories Inc., Cytek Biosciences Inc., Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., Miltenyi Biotec B.V. And Co. KG, Shenzhen Mindray BioMedical Electronics Co. Ltd, OLS OMNI Life Science GmbH and Co. KG, On-Chip Biotechnologies Co. Ltd., Sartorius AG, Sony Group Corp., Stratedigm Inc., Sysmex Corp., Thermo Fisher Scientific Inc., and Union Biometrica Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Flow Cytometer Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 15.2%

Market growth 2024-2028

USD 8170.7 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

12.86

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 32%

Key countries

US, China, UK, Germany, and Canada

Key companies profiled

Abbott Laboratories, Agilent Technologies Inc., Amphasys AG, Apogee Flow Systems Ltd., Becton Dickinson and Co., Bio Rad Laboratories Inc., Cytek Biosciences Inc., Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., Miltenyi Biotec B.V. And Co. KG, Shenzhen Mindray BioMedical Electronics Co. Ltd, OLS OMNI Life Science GmbH and Co. KG, On-Chip Biotechnologies Co. Ltd., Sartorius AG, Sony Group Corp., Stratedigm Inc., Sysmex Corp., Thermo Fisher Scientific Inc., and Union Biometrica Inc.

Market Driver

The Flow Cytometer Market is experiencing significant growth due to the increasing demand for multiparametric data analysis in various industries. Stem cell cultures and fluorescent-labeled antibodies are key applications driving market expansion. Flow cytometry is used extensively in the research and diagnosis of diseases such as cancer, HIV, and autoimmune disorders. FlowMetric Life Sciences, innovators in flow cytometry, provide instruments, software, and flow cytometry services for drug discovery and cell line development. Flow cytometry techniques like Western blotting, immunohistochemistry, and microscopy complement the analysis. Accessories like fluorochrome combinations, liquid handling robotics, and bead-based assays expand the capabilities of flow cytometry. The market caters to biotechnology, life science, and biopharmaceutical research activities, offering point-of-care diagnostics for tuberculosis, sexually transmitted diseases, and other infectious diseases. Digital signal processing enhances data analysis solutions, while cellular diagnostics and immunodeficiency disorders are other major applications. Flow cytometry instruments include microfluidic flow cytometry and PCR, and antibody-based testing is a significant trend. 

Flow cytometry, a laboratory technique used for analyzing and sorting cells, has seen significant advancements in automation over the past few decades. Manual sample preparation and loading have been replaced with instruments that automate these processes. These devices feature digital interfaces and store processed information, reducing the need for human intervention. Integration with other devices and processes increases flexibility, enables continuous sample flow, and decreases processing time and supervision. Modern laboratory equipment can be integrated into a digital ecosystem, ensuring a seamless transition between processes. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

Flow cytometry is a crucial technology in life sciences and biotechnology industries for analyzing cells. It allows for the measurement of multiple parameters, including the use of fluorescent-labeled antibodies and compounds, on single cells. However, handling multiparametric data can be challenging. Stem cell cultures also pose unique difficulties. Flow cytometers, instruments, accessories, and software are essential tools for this technique. In cancer, HIV, and other diseases like leukemia and lymphoma, flow cytometry plays a significant role in diagnosis and drug discovery services. Flow cytometry innovators and contract service providers offer flow cytometry analysis for immune cells, cell line development, and cellular diagnostics. Parameters like digital signal processing and fluorochrome combinations enhance the technology’s capabilities. FlowMetric Life Sciences, liquid handling robotics, and microfluidic flow cytometry are recent advancements. Applications include clinical testing labs, PCR, antibody-based testing, and point-of-care diagnostics for diseases like tuberculosis and sexually transmitted diseases.The flow cytometer market is experiencing significant growth due to the increasing demand for advanced analytical tools in drug discovery and development for infectious and chronic diseases. Flow cytometers are essential instruments in this process, offering precise and accurate data. However, the high cost of these instruments poses a challenge to market expansion. Prices range from USD100,200 to USD500,200 for a single unit, with additional expenses for reagents, markers, consumables, and accessories. This investment is justified by the valuable data generated, but it remains a significant consideration for research organizations and pharmaceutical companies.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This flow cytometer market report extensively covers market segmentation by

Product1.1 Reagents and consumables1.2 Instruments1.3 OthersEnd-user2.1 Pharmaceutical industry2.2 Health and diagnostic centers2.3 OthersGeography3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Reagents and consumables- The global flow cytometer market is driven by the essential role of reagents and consumables in various applications across clinical diagnostics, research, and biopharmaceutical industries. Reagents, including fluorescently labeled antibodies, viability dyes, and calibration beads, enhance cellular property detection and quantification. Innovation in reagent composition leads to more effective products for molecular and cellular biology studies. Thermo Fisher Scientific and Bio-Rad Laboratories are key vendors offering a wide range of assays, antibodies, and reagents for flow cytometry. The market growth is fueled by the increasing prevalence of chronic diseases, advancements in personalized medicine, and research activities in immunology and cancer biology. High-quality consumables ensure sample integrity and accurate flow cytometric analyses. Investments in new antibody and Deoxo-Fluor reagents will further drive demand.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

Flow cytometry is a powerful analytical technique used in various fields of life science, biotechnology, and biopharmaceutical research activities. This technique enables the analysis of multiparametric data from individual cells using fluorescent-labeled antibodies or compounds. Stem cell cultures are increasingly utilizing flow cytometry for characterization and sorting. Control parameters such as forward and side scatter are used to identify and exclude debris and aggregates. Data analysis solutions help researchers make sense of the complex data generated. Flow cytometry services offer expertise and equipment for those without access to their own instruments. Flow cytometry is used in the diagnosis and research of various diseases, including autoimmune disorders, infectious diseases like HIV/AIDS, and cancer, as well as immunodeficiency disorders. Techniques such as Western blotting, immunohistochemistry, microscopy, and PCR are often used in conjunction with flow cytometry. Microfluidic flow cytometry and antibody-based testing are emerging applications. Flow cytometer instruments continue to advance, offering increased sensitivity, speed, and multiplexing capabilities.

Market Research Overview

Flow cytometry is a powerful analytical technology used to measure and analyze the physical and chemical characteristics of cells, including their size, shape, and the presence of specific markers. This technique employs the use of flow cytometers, instruments that pass single cells in suspension through a laser beam, exciting fluorescent-labeled antibodies or compounds attached to the cells. Multiparametric data is generated, allowing for the simultaneous measurement of multiple parameters. Stem cell cultures and immune cells are common applications, with flow cytometry playing a crucial role in cancer, HIV, leukemia, lymphoma, autoimmune disorders, infectious diseases, and drug discovery services. Flow cytometry analysis is essential for cell line development, immunodeficiency disorders, and biotechnology research activities. Innovations in flow cytometry include microfluidic flow cytometry, digital signal processing, point-of-care diagnostics, and cell-based flow cytometry. Accessories, software, and bead-based assays are also integral components of the flow cytometry ecosystem. FlowMetric Life Sciences and other contract service providers offer flow cytometry services to researchers and clinical testing labs. Fluorochrome combinations, liquid handling robotics, and PCR are additional tools used in conjunction with flow cytometry for various applications, including drug development activities and antibody-based testing for diseases like tuberculosis and sexually transmitted diseases.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductReagents And ConsumablesInstrumentsOthersEnd-userPharmaceutical IndustryHealth And Diagnostic CentersOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/flow-cytometer-market-to-expand-by-usd-8-17-billion-2024-2028-rising-rd-investments-drive-growth-report-on-ais-impact-on-market-trends—technavio-302315806.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

QuickStart Acquires Career Development Solutions to Accelerate Growth in Government and Enterprise Businesses

Published

on

By

QuickStart has acquired Career Development Solutions (CDS) to expand its IT training capabilities for government and enterprise clients. This partnership leverages CDS’s expertise in workforce development and QuickStart’s AI-powered learning platform to address critical IT skills gaps and support career advancement for individuals and employers.

AUSTIN, Texas, Dec. 12, 2024 /PRNewswire-PRWeb/ — QuickStart, a leader in online IT workforce development, is pleased to announce the acquisition of Career Development Solutions (CDS), a leading provider of IT training to government and enterprise clients.

CDS is a recognized leader in career readiness and workforce training, with extensive expertise in career transition support, employer partnerships, and government funding programs. The acquisition accelerates QuickStart’s already rapidly growing B2G business by adding significant relationships and business in Arizona, California, Nevada, and Utah. Additionally, the CDS team adds depth of B2B experience in helping employers upskill and reskill IT teams across a range of subject areas.

“This acquisition represents an incredible opportunity to combine the strengths of QuickStart and Career Development Solutions, enhancing our ability to deliver impactful training programs that ensure learners are prepared for today’s fast-evolving IT workforce,” said Bryan Kenna, CEO of QuickStart. “Together, we will rapidly expand the solutions we provide to individuals and government and enterprise partners.”

The acquisition enhances QuickStart’s dedication to providing training that addresses individual and employer needs. Leveraging a proprietary AI-powered learning platform, QuickStart develops highly targeted, skills-based career pathways and training plans to close critical digital skills gaps and provide exceptional outcomes for learners and employers.

Ryan Landry, President and Managing Director at Career Development Solutions, stated, “The acquisition of Career Development Solutions into the QuickStart family makes us, overnight, a tech-enabled workforce development ecosystem. We now handle everything from talent development to talent acquisition, providing solutions that truly lower customer costs. It’s an exciting time to be a business leader working with our tools and systems.”

For more information about QuickStart, visit https://www.quickstart.com/

To learn more about Career Development Solutions, visit www.careerdevelopmentsolutions.com

About QuickStart

QuickStart offers IT training for emerging and established professionals in the field. For over 35 years, QuickStart has partnered with IT experts and hiring managers to develop industry-aligned certificate courses and bootcamp training programs. Through online learning tailored to the latest developments in AWS (Amazon Web Services), Cisco, CompTIA, Microsoft Azure, and more, QuickStart empowers entry-level and experienced IT professionals with leading-edge skills for the workforce.

To best prepare students for professional success, QuickStart offers personalized learning plans and career support services, including resume building, coaching, and job search assistance. Students emerge ready to add value to their organizations, improve their earning power, and achieve their professional goals. Follow QuickStart on LinkedIn, Facebook, Instagram, and X.

About Career Development Solutions

Career Development Solutions offers career training programs to better your life. We give students new opportunities through globally recognized career training programs. We provide industry-leading certifications, training preparation, focused career paths, award-winning teachers, and the support you deserve.

Our career development programs match job training with industry-recognized stackable certifications built into our training programs. We create and deliver training programs that focus on in-demand sectors, including Information Technology and Manufacturing, along with closing the Technology Gap that is hindering individuals across our county from gaining employment. For more information, please visit the Career Development Solutions website or follow us on Facebook, LinkedIn, Instagram, and YouTube.

Media Contact

Imelda Wistey, QuickStart Learning, 1 (855) 800-8240, quickstart@quickstart.com, https://www.quickstart.com

View original content:https://www.prweb.com/releases/quickstart-acquires-career-development-solutions-to-accelerate-growth-in-government-and-enterprise-businesses-302329970.html

SOURCE QuickStart Learning

Continue Reading

Technology

ImageSource, Inc. Reinvigorates Executive Team

Published

on

By

ImageSource, Inc. Promotes Phong Hoang to Chief Product Officer

OLYMPIA, Wash., Dec. 12, 2024 /PRNewswire/ — ImageSource, Inc., the manufacturer of ILINX, the world’s most flexible process-improvement platform, is proud to announce the promotion of Phong Hoang to Chief Product Officer. Previously serving as Vice President of Software Development, Phong has been instrumental in shaping ILINX software into a premier enterprise process-improvement platform.

Since joining ImageSource in 2006, Phong has led the evolution of the platform through the ILINX software development lifecycle—including design, development, and testing—fostering a culture of innovation and technical excellence. Under his leadership, the ILINX platform has grown from its initial concept of point solution to fill third-party software gaps to a robust suite of software modules that drive efficiency and transformation for customers across industries.

“Phong’s vision and leadership have been pivotal to the evolution of ILINX as a flexible, scalable solution for modern business challenges,” said Terry Sutherland, CEO of ImageSource. “His ability to inspire and direct development teams has been key to our platform’s success and global adoption.”

Phong brings a wealth of technical expertise to his role, holding a Bachelor of Science in Computer Science from California State University, Long Beach. His background includes proficiency in C#/.NET, Java, C++, Web Service, and Windows Installer, as well as valuable industry experience at Kofax, Microsoft, and Pierce County before joining ImageSource.

As Chief Product Officer, Phong will continue to guide the future of the ILINX platform, ensuring its capabilities align with emerging market needs and deliver transformative outcomes for ImageSource customer-partners.

About ImageSource
ImageSource, Inc. makes process innovation easy with advanced solutions built on ILINX®, the world’s most flexible process-improvement platform, delivered by a team of experts committed to customer-partner success. Leveraging proven technology and deep implementation expertise, ImageSource empowers leading enterprises and government organizations to reduce risk, modernize operations, unlock revenue, and transform the customer experience. For more information, visit www.imagesourceinc.com, or call (360) 943-9273.

View original content to download multimedia:https://www.prnewswire.com/news-releases/imagesource-inc-reinvigorates-executive-team-302329309.html

SOURCE ImageSource, Inc.

Continue Reading

Technology

VANTIS VASCULAR CLOSES $10M IN SERIES B-1 PREFERRED FINANCING

Published

on

By

Funds will be used to initiate US commercialization of its CrossFAST™ Integrated Microcatheter Advanced Delivery System

SAN JOSE, Calif., Dec. 12, 2024 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians with a passion to revolutionize vascular interventions, today announced the successful closing of $10 million Series B-1 preferred financing, following a raise of $30 million to date from high-net-worth individuals and National Institute of Health grants.

The CrossFAST Advanced Delivery System is commercially available in the US as part of a limited market release.

“We are proud to have the ongoing support of a strong group of investors who share our vision of transforming how complex interventional procedures are performed,” said Jason Turner, Chief Executive Officer at Vantis Vascular. “This funding is a critical milestone for Vantis and will allow us to continue our ongoing product development efforts, expand our team and initiate US commercialization of the CrossFAST Advanced Delivery System for complex high-risk PCI procedures.”

The CrossFAST System is the first and only dual monorail microcatheter advanced delivery system purpose-built for complex coronary and peripheral interventions. Unlike guide extension catheters, which have limited ability to reach targeted areas in high-risk PCIs and demonstrated risk of vessel trauma and damage to previously placed stents, the CrossFAST Advanced Delivery System incorporates an integrated microcatheter with a seamless transition to lower the risk of these adverse events during catheter delivery. The CrossFAST System is powered by DuoPRO™ Interlocking Technology, a novel mechanism coupling the microcatheter to the outer delivery catheter, allowing the system to be advanced as one unit for enhanced pushability and efficient navigation, a significant limitation of guide extension catheters, especially in complex high-risk procedures.

“With the completion of this financing, we plan to initiate the limited market release of the CrossFAST System in the United States,” commented Gary McCord, Chief Commercial Officer at Vantis Vascular. “We are confident that CrossFAST can safely navigate calcified and tortuous anatomy with ease, empowering physicians to deliver life-saving therapies to patients more effectively than ever before.”

The CrossFAST Integrated Microcatheter Advanced Delivery System is commercially available in the United States as part of a limited market release. Full market release is planned in 2025.

About Vantis Vascular:

Vantis Vascular, Inc. is a medical technology company dedicated to revolutionizing vascular interventions. Founded by physicians, Vantis develops performance-driven technologies that aim to provide faster, safer and more effective treatments. With a focus on innovation and patient-centric solutions, Vantis is committed to advancing the field of interventional cardiology and improving patient outcomes worldwide.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vantis-vascular-closes-10m-in-series-b-1-preferred-financing-302330527.html

SOURCE Vantis Vascular, Inc.

Continue Reading

Trending